Tesamorelin vs Sermorelin
Which Is Right for You? Complete Comparison (2026)
Tesamorelin vs Sermorelin — FDA-approved GHRH analog for visceral fat reduction vs first-generation GHRH peptide for anti-aging.
Tesamorelin vs Sermorelin: At a Glance
- ✓FDA-approved synthetic GHRH analogue (Egrifta)
- ✓Stimulates natural pulsatile GH release from the pituitary
- ✓Approved specifically for HIV-associated lipodystrophy
- ✓Reduces visceral adipose tissue and liver fat
- ✓Does not cause GH desensitization
- ✓Synthetic GHRH(1-29) — the bioactive fragment of natural GHRH
- ✓Stimulates natural pulsatile GH release from the pituitary
- ✓Previously FDA-approved (Geref) for pediatric GH deficiency
- ✓Does not cause GH desensitization with chronic use
- ✓Half-life approximately 10-20 minutes
Detailed Comparison
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Mechanism | GHRH analogue | Growth hormone releasing hormone analogueBest |
| Dosing | 2 mg SC daily | 200-500 mcg SC daily at bedtime |
| Administration | Subcutaneous injection daily | Subcutaneous injection |
| Half-life | ~26-38 minutes | ~10-20 minutes |
| FDA Status | FDA-approved (Egrifta — for HIV lipodystrophy) | Previously FDA-approved (discontinued commercially) |
| Key Trial | Falutz J et al. NEJM 2007 — visceral fat reduction in HIV | Prakash A et al. BioDrugs 1999 — clinical review |
| Side Effects | Injection site reactions, joint pain, peripheral edema, paresthesia | Injection site reactions, flushing, headache — generally well-tolerated |
Which Should You Choose?
Tesamorelin (Egrifta) (ghrh analogue) and Sermorelin (GRF 1-29) (growth hormone releasing hormone analogue) serve different clinical roles despite both being in the GHRH analogue space. Tesamorelin (Egrifta) fda-approved synthetic ghrh analogue that stimulates pulsatile gh release. Sermorelin (GRF 1-29) synthetic 29-amino-acid analogue of natural ghrh that stimulates physiological gh release from the pituitary.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Tesamorelin and Sermorelin
Choosing between Tesamorelin and Sermorelin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Tesamorelin and Sermorelin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Tesamorelin vs Sermorelin: Frequently Asked Questions
Tesamorelin (Egrifta) is a ghrh analogue while Sermorelin (GRF 1-29) is a growth hormone releasing hormone analogue. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Tesamorelin (Egrifta) works as a ghrh analogue (2 mg SC daily), while Sermorelin (GRF 1-29) is a growth hormone releasing hormone analogue (200-500 mcg SC daily at bedtime). They have different half-lives (~26-38 minutes vs ~10-20 minutes), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Tesamorelin or Sermorelin in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.